CUE biotech catalysts & pipeline

CUE BIOPHARMA INC · Data as of 2026-10-25

Upcoming catalysts

CUE-401 — Initial data

H2 2026

We anticipate receiving human safety data in the second half of 2026 and human proof-of-concept data in the second half of 2027.

Source filing

CUE-401 — IND submission

Late 2026

Company anticipates submitting an IND to the FDA and initiating a Phase 1 clinical study by year-end 2026

Source filing

CUE-100 series — IND submission

2027

Compelling data generated in preclinical models of multiple solid tumors, including pancreatic and ovarian, demonstrates the clinical potential of this novel immunotherapy approach with IND enabling studies on track for 2027 submission

Source filing

CUE-401 — Initial data

H2 2027

We anticipate receiving human safety data in the second half of 2026 and human proof-of-concept data in the second half of 2027.

Source filing

Explore the free biotech catalyst calendar